glp 1 agonists review Glucagon‐like peptide agonists: A prospective - Mariam - 2024 - Endocrinology, Diabetes & Metabolism glp 1 agonist review article
Description
Considering this evidence, increasing neurogenesis in the brain through the GLP-1 pathway may provide a novel approach for improving depressive-like behavior in patients with depression

These drugs include exenatide (Byetta, short-acting
Amongst the three predominant HF phenotypes (HF with preserved, mildly reduced or reduced ejection fraction

Compensation for blood pressure reduction and stimulation of the sinus node and sympathetic nervous system appear to speed up the pulse
doi: 10.1078/0944-7113-00081 261 RituMNandiniJ

The Promise of GLP-1 Drugs: More Than Just Diabetes Management When GLP-1 (Glucagon-Like Peptide-1) receptor agonists first hit the market, they were hailed as a breakthrough in type 2 diabetes
